Novartis to use gene editing tool with CAR-T therapies
This article was originally published in Scrip
Executive Summary
Novartis has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using the CRISPR genome editing technology. It simultaneously entered a deal with Caribou Biosciences for the development of drug discovery tools in the nascent field.